Omega-3 polyunsaturated fatty acids and pulmonary arterial hypertension: Insights and perspectives.

Autor: Massaro M; Institute of Clinical Physiology (IFC), National Research Council (CNR), Lecce, Italy., Quarta S; Institute of Clinical Physiology (IFC), National Research Council (CNR), Lecce, Italy., Calabriso N; Institute of Clinical Physiology (IFC), National Research Council (CNR), Lecce, Italy., Carluccio MA; Institute of Clinical Physiology (IFC), National Research Council (CNR), Lecce, Italy., Scoditti E; Institute of Clinical Physiology (IFC), National Research Council (CNR), Lecce, Italy., Mancuso P; Department of Nutritional Sciences and the Program in Immunology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA., De Caterina R; Cardiology Division, Pisa University Hospital, Pisa, Italy., Madonna R; Cardiology Division, Pisa University Hospital, Pisa, Italy.
Jazyk: angličtina
Zdroj: European journal of clinical investigation [Eur J Clin Invest] 2024 Nov; Vol. 54 (11), pp. e14277. Date of Electronic Publication: 2024 Jun 28.
DOI: 10.1111/eci.14277
Abstrakt: Pulmonary arterial hypertension (PAH) is a rare and progressive disorder that affects the pulmonary vasculature. Although recent developments in pharmacotherapy have extended the life expectancy of PAH patients, their 5-year survival remains unacceptably low, underscoring the need for multitarget and more comprehensive approaches to managing the disease. This should incorporate not only medical, but also lifestyle interventions, including dietary changes and the use of nutraceutical support. Among these strategies, n-3 polyunsaturated fatty acids (n-3 PUFAs) are emerging as promising agents able to counteract the inflammatory component of PAH. In this narrative review, we aim at analysing the preclinical evidence for the impact of n-3 PUFAs on the pathogenesis and the course of PAH. Although evidence for the role of n-3 PUFAs deficiencies in the development and progression of PAH in humans is limited, preclinical studies suggest that these dietary components may influence several aspects of the pathobiology of PAH. Further clinical research should test the efficacy of n-3 PUFAs on top of approved clinical management. These studies will provide evidence on whether n-3 PUFAs can genuinely serve as a valuable tool to enhance the efficacy of pharmacotherapy in the treatment of PAH.
(© 2024 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: